Latest news

Daily Snap - 15. August 2025

Daily Snap - 15. August 2025

Joachim Eeckhout
New CD40 antibody shrinks metastatic tumors with minimal side effects

New CD40 antibody shrinks metastatic tumors with minimal side effects

Eduardo Longoria
Eli Lilly bets $1.3B on Superluminal's GPCR platform to target obesity and heart disease

Eli Lilly bets $1.3B on Superluminal's GPCR platform to target obesity and heart disease

Eduardo Longoria
Daily Snap - 14. August 2025

Daily Snap - 14. August 2025

Joachim Eeckhout
Response’s RDX-002 shows promise for keeping weight off after GLP-1 drugs

Response’s RDX-002 shows promise for keeping weight off after GLP-1 drugs

Eduardo Longoria
Vor’s pivot to autoimmune drugs gains traction with Sjögren’s trial success

Vor’s pivot to autoimmune drugs gains traction with Sjögren’s trial success

Eduardo Longoria
Daily Snap - 13. August 2025

Daily Snap - 13. August 2025

Joachim Eeckhout
Bayer bets $1.3B on Kumquat's KRAS inhibitor cancer drug

Bayer bets $1.3B on Kumquat's KRAS inhibitor cancer drug

Joachim Eeckhout
FDA approves Insmed’s Brinsupri, the first DPP1 inhibitor on the market

FDA approves Insmed’s Brinsupri, the first DPP1 inhibitor on the market

Joachim Eeckhout
Daily Snap - 12. August 2025

Daily Snap - 12. August 2025

Joachim Eeckhout
IO Biotech eyes FDA nod for skin cancer vaccine despite narrow trial miss

IO Biotech eyes FDA nod for skin cancer vaccine despite narrow trial miss

Joachim Eeckhout
Novartis scores a Phase 3 win in Sjögren’s syndrome, salvaging value from its $2.9B MorphoSys buy

Novartis scores a Phase 3 win in Sjögren’s syndrome, salvaging value from its $2.9B MorphoSys buy

Joachim Eeckhout
FirstBack
1234567
Next Last